ASCO Stage IV Non-Small-Cell Lung Cancer without Driver Alterations Systemic Therapy Guidelines Pocket Guide Cover

Stage IV Non-Small-Cell Lung Cancer GUIDELINES Pocket Guide

Approved By

American Society of Clinical Oncology

Digital Subscription $4.99 Add to Cart
Print $9.95 Add to Cart
Free Sample

The Digital version of the ASCO Stage IV Non-Small-Cell Lung Cancer without Driver Alterations Systemic Therapy GUIDELINES contains all the same great information found in the Pocket Guide, and can be accessed on Mobile devices and online:

  • ASCO members receive free digital access at www.asco.org/guideline-pocket-cards
  • Price: $4.99
    • Subscribe to additional guideline titles for discounted rates
  • Includes automatic updates during the term of your subscription
  • CPT® and ICD10 codes can be added to certain guidelines for an additional fee
  • Supported platforms
    • iPhone and iPad
    • Android phones and tablets
    • Online (internet connection required)
  • Content on the Guideline Central mobile app accessible without an internet connection
    • Access to additional guideline summaries, clinical calculators, and more

For mobile access, download the free app from the App Store or Google Play and use the same email address and password as the website to login.

For individual use only; contact us for group and site licenses.

The Stage IV Non-Small Cell Lung Cancer without Driver Alterations Pocket Guide is based on the latest guidelines of the American Society of Clinical Oncology and was developed with their collaboration. It contains graded recommendations for immune checkpoint therapy of Non–Small-Cell Lung Cancer without Driver Alterations.

  • Multifold
  • 6 Pages
  • 80# Diamond Silk Cover with Satin Aqueous Coating
  • 4.25″ x 7.25″
  • Introduction
  • Table
    • Definitions of PD-L1 Tumor Proportion Score (TPS) level in this guideline
  • Treatment Recommendations
    • For patients with high PD-L1 expression (TPS ≥50%) and non-squamous cell carcinoma (non-SCC), in the absence of contraindications to immune checkpoint therapies
    • For patients with negative (TPS 0%) and low positive (TPS 1% to 49%) PD-L1 expression and non-SCC, in the absence of contraindications to immune checkpoint therapies
    • For patients with high PD-L1 expression (TPS ≥50%) and squamous cell carcinoma (SCC), in the absence of contraindications to immune checkpoint therapy
    • For patients with negative (TPS 0%) and/or low positive (TPS 1% to 49%) PD-L1 expression and SCC, in the absence of contraindications to immune checkpoint therapies

Founded in 1964, the American Society of Clinical Oncology is the world's leading professional organization for physicians and oncology professionals caring for people with cancer.

  • Guideline Pricing

  • Single Title
    $4.99 / year
  • Any 5 Titles
    $23.99 / year
  • Any 10 Titles
    $41.99 / year
  • Any 35 Titles
    $74.99 / year
  • All Available Titles
    $169.99 / year

To get started, log in or create your free account Create Account